TVTX vs VERA: How Travere Therapeutics and Vera Therapeutics Compare (2026)

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. TVTX and VERA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined TVTX and VERA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Travere Therapeutics (Nasdaq: TVTX) develops and sells treatments for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is a once-daily oral dual endothelin and angiotensin receptor antagonist that received full FDA approval for IgA nephropathy in September 2024 and, in April 2026, became the first FDA-approved therapy specifically for focal segmental glomerulosclerosis (FSGS). The company also sells THIOLA and THIOLA EC (tiopronin) for cystinuria, a small but steady legacy franchise, and partners FILSPARI outside the US with CSL Vifor in Europe and Everest Medicines in parts of Asia. Behind the commercial business sits a nephrology and metabolic pipeline led by pegtibatinase for classical homocystinuria and the in-licensed BTK inhibitor civorebrutinib for immune-mediated kidney diseases including primary membranous nephropathy.

Full TVTX guide

Vera Therapeutics is a biotechnology company focused on autoimmune kidney disease. Its lead asset is atacicept (brand name TRUTAKNA, atacicept-vymj), a subcutaneous fusion protein that blocks two B-cell signaling proteins, BAFF and APRIL, which drive the antibody production behind IgA nephropathy (IgAN), a progressive disease that can lead to kidney failure. In the ORIGIN Phase 3 trial, atacicept cut proteinuria (protein leaking into urine, a key marker of kidney damage) by about 46% from baseline and roughly 42% versus placebo at 36 weeks, and on July 7, 2026 the FDA granted accelerated approval, making it the first dual BAFF/APRIL inhibitor cleared for IgAN.

Full VERA guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• TVTX drivers: The FSGS launch, a market with no prior approved therapy; Compounding the IgA nephropathy base.
• VERA drivers: TRUTAKNA commercial launch; Full approval and eGFR data.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Single-product concentration is the defining risk: FILSPARI is the overwhelming majority of revenue, so any safety signal, label change, reimbursement setback or competitive loss hits the whole company rather than one segment. For VERA, vera has no meaningful trailing product revenue and funds itself through large operating losses, so it depends on its cash balance and capital markets to reach sustained profitability.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick TVTX if you believe its drivers more; VERA if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the TVTX and VERA guides.

TVTX. There is no meaningful P/E here because Travere is still running a small net loss, so the market is valuing it on the revenue trajectory and on how close FILSPARI gets to the stated $3B-plus peak ambition. The stock has moved violently in both directions over the past year, with a 52-week range of roughly $15.60 to $66.24, which tells you how much of the price is regulatory and launch expectation rather than trailing results. At ~10x sales with revenue nearly doubling in the lead product, the multiple is not extreme for a growth biotech but it does assume the launch curve holds.

VERA. As of July 2026, Vera's valuation reflects expectations for atacicept sales rather than current financials, since the company reported no product revenue and a large net loss in the first quarter of 2026. Its roughly $597 million cash position gives it runway to fund the TRUTAKNA launch. Any earnings multiple is not meaningful until commercial revenue builds, so the stock trades on the addressable market and launch trajectory.

Headline figures (approximate, August 2026): TVTX shows revenue (ttm) ~$591M, up ~77% year over year, q2 2026 revenue ~$169.6M total, with FILSPARI US net sales of ~$141.1M (+96% YoY), net income (ttm) ~-$43M net loss (~$0.48 loss per share); Q2 GAAP loss ~$34.8M, gross margin (ttm) ~98.6%, with trailing free cash flow of ~$93M; VERA shows revenue (ttm) ~$0 (pre-commercial through Q1 2026), net loss (q1 2026) ~$121.0M, net loss per share (q1 2026) ~$1.69, cash & marketable securities ~$596.8M (as of Mar 31, 2026).

TVTX and VERA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined TVTX and VERA exposure against your real portfolio. It is not an investment adviser.